Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2008

Open Access 01-12-2008 | Research

Short- and long-term outcomes of single bare metal stent versus drug eluting stent in nondiabetic patients with a simple de novo lesion in the middle and large vessel

Authors: Yue-jin Yang, Sheng Kang, Bo Xu, Ji-lin Chen, Shu-bin Qiao, Xue-wen Qin, Min Yao, Jue Chen, Yong-jian Wu, Hai-bo Liu, Jin-qing Yuan, Shi-jie You, Jian-jun Li, Jun Dai, Run-lin Gao

Published in: Journal of Translational Medicine | Issue 1/2008

Login to get access

Abstract

Objective

This study was aimed to investigate the short- and long-term outcomes of percutaneous coronary intervention (PCI) between single bare metal stent (BMS) and single drug eluting stent (DES) in nondiabetic patients with a simple de novo lesion in the middle and large vessel.

Methods

Two hundred and thirty-five consecutive patients with a simple de novo lesion in the middle and large vessel were treated with BMS or DES in our hospital from Apr. 2004 to Dec. 2004.
The inclusion criteria: a simple de novo lesion in the middle and large vessel, stent diameter ≥ 3.0 mm, stent length ≤ 18 mm, the exclusion criteria: diabetes mellitus, left main trunk disease and left ventricular ejection fraction ≤ 30%. Of them, there were 150 patients in BMS group and 85 patients in DES group, and the rates of lost to follow up were 6.7% and 1.2% respectively.

Results

BMS group had lower hypercholesteremia rate (22.0% vs 38.8%) and higher proportion of TIMI grade 0 (12% vs 1.2%) than DES group (all P < 0.05), but both groups had similar stent length (16.16 ± 2.81 mm vs 16.06 ± 2.46 mm) and stent diameter (3.85 ± 3.07 mm vs 3.19 ± 0.24 mm) after procedure, in-segment restenosis rate (0% vs 1.2%) and target lesion revascularization (TLR, 2.0% vs 2.4%) at 6-month follow-up (all P > 0.05). No difference was found in TLR (1.3% vs 1.2%, P = 1.00) and recurrent myocardial infarction (Re-MI) (0% vs 1.2%, P = 0.36), cardiac death (0.7% vs 1.2%, P = 1.00) between 1- and 3-year. So were TLR (6.0% vs 5.9%, P = 0.97), Re-MI (0% vs 2.4%, P = 0.06), cardiac death (2.0% vs 3.5%, P = 0.48) and major adverse cardiac events (MACE, 8.7% vs 10.6%, P = 0.63), cardiac death-free cumulative survival (98.7% vs 97.7%, P = 0.56), TLR-free cumulative survival (94.0% vs 94.1%, P = 0.98) and Re-MI-free cumulative survival (100% vs 97.7%, P = 0.06) at 3-year follow-up.

Conclusion

The single BMS has similar efficacy and safety to single DES in nondiabetic patients with a simple de novo lesion in the middle and large vessel at short- and long-term follow-up.
Appendix
Available only for authorised users
Literature
1.
Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003, 349 (14): 1315-23. 10.1056/NEJMoa035071.CrossRefPubMed
2.
Holmes DR, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE: Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004, 109 (5): 634-40. 10.1161/01.CIR.0000112572.57794.22.CrossRefPubMed
3.
Weisz G, Leon MB, Holmes DR, Kereiakes DJ, Clark MR, Cohen BM, Ellis SG, Coleman P, Hill C, Shi C, Cutlip DE, Kuntz RE, Moses JW: Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol. 2006, 47 (7): 1350-5. 10.1016/j.jacc.2005.11.077.CrossRefPubMed
4.
Lemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, Tanabe K, Hoye A, Degertekin M, Daemen J, McFadden E, Hofma S, Smits PC, de Feyter P, Giessen van der WJ, van Domburg RT, Serruys PW: Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation. 2003, 108 (3): 257-60. 10.1161/01.CIR.0000083366.33686.11.CrossRefPubMed
5.
Colombo A, Orlic D, Stankovic G, Corvaja N, Spanos V, Montorfano M, Liistro F, Carlino M, Airoldi F, Chieffo A, Di Mario C: Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation. 2003, 107 (17): 2178-80. 10.1161/01.CIR.0000070592.04766.36.CrossRefPubMed
6.
Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C: Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006, 48 (12): 2584-91. 10.1016/j.jacc.2006.10.026.CrossRefPubMed
7.
Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL: Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006, 119 (12): 1056-61. 10.1016/j.amjmed.2006.01.023.CrossRefPubMed
8.
Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB: Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999, 100 (18): 1872-8.CrossRefPubMed
9.
Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A, Kastrati A: Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol. 2006, 48 (7): 1304-9. 10.1016/j.jacc.2006.05.068.CrossRefPubMed
10.
Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB, Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WL: Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation. 1988, 78 (2): 486-502.CrossRefPubMed
11.
Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM: Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Circulation. 1990, 82 (4): 1193-202.CrossRefPubMed
12.
EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998, 352 (9122): 87-92. 10.1016/S0140-6736(98)06113-3.CrossRef
13.
Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004, 350 (3): 221-31. 10.1056/NEJMoa032441.CrossRefPubMed
14.
Foley DP, Melkert R, Serruys PW: Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty. Circulation. 1994, 90 (3): 1239-51.CrossRefPubMed
15.
Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW: Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001, 103 (2): 192-5.CrossRefPubMed
16.
Rensing BJ, Vos J, Smits PC, Foley DP, Brand van den MJ, Giessen van der WJ, de Feijter PJ, Serruys PW: Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J. 2001, 22 (22): 2125-30. 10.1053/euhj.2001.2892.CrossRefPubMed
17.
Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW: Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001, 104 (17): 2007-11. 10.1161/hc4201.098056.CrossRefPubMed
18.
Regar E, Serruys PW, Bode C, Holubarsch C, Guermonprez JL, Wijns W, Bartorelli A, Constantini C, Degertekin M, Tanabe K, Disco C, Wuelfert E, Morice MC: Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation. 2002, 106 (15): 1949-56. 10.1161/01.CIR.0000034045.36219.12.CrossRefPubMed
19.
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002, 346 (23): 1773-80. 10.1056/NEJMoa012843.CrossRefPubMed
20.
Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, Giessen van der W, Colombo A, Seabra-Gomes R, Kiemeneij F, Ruygrok P, Ormiston J, Emanuelsson H, Fajadet J, Haude M, Klugmann S, Morel MA: Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998, 352 (9129): 673-81. 10.1016/S0140-6736(97)11128-X.CrossRefPubMed
21.
Laham RJ, Carrozza JP, Berger C, Cohen DJ, Kuntz RE, Baim DS: Long-term (4- to 6-year) outcome of Palmaz-Schatz stenting: paucity of late clinical stent-related problems. J Am Coll Cardiol. 1996, 28 (4): 820-6. 10.1016/S0735-1097(96)00244-6.CrossRefPubMed
22.
23.
Kastrati A, Schömig A, Elezi S, Schühlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ: Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997, 30 (6): 1428-36. 10.1016/S0735-1097(97)00334-3.CrossRefPubMed
24.
Bauters C, Hubert E, Prat A, Bougrimi K, Van Belle E, McFadden EP, Amouyel P, Lablanche JM, Bertrand M: Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol. 1998, 31 (6): 1291-8. 10.1016/S0735-1097(98)00076-X.CrossRefPubMed
25.
Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME: Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003, 108 (7): 788-94. 10.1161/01.CIR.0000086926.62288.A6.CrossRefPubMed
26.
Halkin A, Stone GW: Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. J Interv Cardiol. 2004, 17 (5): 271-82. 10.1111/j.1540-8183.2004.04040.x.CrossRefPubMed
27.
Jonas M, Resnic FS, Levin AD, Arora N, Rogers CD: Transition from bare metal to drug eluting stenting in contemporary US practice: effect on incidence and predictors of clinically driven target lesion revascularization. Catheter Cardiovasc Interv. 2007, 70 (2): 175-83. 10.1002/ccd.21123.CrossRefPubMed
28.
Mishra S, Wolfram RM, Torguson R, Chu WW, Xue Z, Gevorkian N, Donekal S, Chan R, Pichard AD, Satler LF, Kent KM, Waksman R: Comparison of effectiveness and safety of drug-eluting stents versus vascular brachytherapy for saphenous vein graft in-stent restenosis. Am J Cardiol. 2006, 97 (9): 1303-7. 10.1016/j.amjcard.2005.11.064.CrossRefPubMed
29.
Holmes DR, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA: Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA. 2006, 295 (11): 1264-73. 10.1001/jama.295.11.1264.CrossRefPubMed
30.
Dibra A, Kastrati A, Alfonso F, Seyfarth M, Pérez-Vizcayno MJ, Mehilli J, Schömig A: Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol. 2007, 49 (5): 616-23. 10.1016/j.jacc.2006.10.049.CrossRefPubMed
31.
Moon JY, Chung JW, Kim JH, Ahn YK, Jeong MH: Simultaneous subacute stent thrombosis of two sirolimus-eluting stents in a patient treated by ReoPro, thrombus aspiration and triple anti-platelet agents. Int J Cardiol. 2007 Oct 1,
32.
Farb A, Boam AB: Stent thrombosis redux – the FDA perspective. N Engl J Med. 2007, 356 (10): 984-7. 10.1056/NEJMp068304.CrossRefPubMed
33.
Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS, Ho KK, Cohen DJ, Garcia LA, Cutlip DE, Carrozza JP: Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation. 2004, 109 (16): 1930-2. 10.1161/01.CIR.0000127105.99982.21.CrossRefPubMed
34.
Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, Han KH, Lee CW, Kang DH, Song JK, Kim JJ, Park SJ: Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005, 46 (10): 1833-7. 10.1016/j.jacc.2005.07.048.CrossRefPubMed
35.
Chen JP: Very late drug-eluting stent thrombosis and cardiogenic shock: 1,249 days after implantation. J Invasive Cardiol. 2007, 19 (12): E381-4.PubMed
36.
Zhang F, Qian J, Ge J: Very late stent thrombosis in late stent malapposition after sirolimus-eluting stent implantation. Int Heart J. 2007, 48 (5): 591-6. 10.1536/ihj.48.591.CrossRefPubMed
37.
Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C: Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006, 48 (12): 2584-91. 10.1016/j.jacc.2006.10.026.CrossRefPubMed
38.
Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L: Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007, 356 (10): 1009-19. 10.1056/NEJMoa067722.CrossRefPubMed
39.
Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, Cremonesi A, Percoco G, Varani E, Magnavacchi P, Guastaroba P, Grilli R, Maresta A: Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation. 2007, 115 (25): 3181-8. 10.1161/CIRCULATIONAHA.106.667592.CrossRefPubMed
40.
Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HH, Bottcher M, Lassen JF, Krussel LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP, Soerensen HT, Thuesen L: Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol. 2007, 50 (5): 463-70. 10.1016/j.jacc.2007.06.002.CrossRefPubMed
41.
Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB: Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007, 356 (10): 998-1008. 10.1056/NEJMoa067193.CrossRefPubMed
42.
Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE: Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007, 356 (10): 1020-9. 10.1056/NEJMoa067731.CrossRefPubMed
Metadata
Title
Short- and long-term outcomes of single bare metal stent versus drug eluting stent in nondiabetic patients with a simple de novo lesion in the middle and large vessel
Authors
Yue-jin Yang
Sheng Kang
Bo Xu
Ji-lin Chen
Shu-bin Qiao
Xue-wen Qin
Min Yao
Jue Chen
Yong-jian Wu
Hai-bo Liu
Jin-qing Yuan
Shi-jie You
Jian-jun Li
Jun Dai
Run-lin Gao
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2008
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-6-42

Other articles of this Issue 1/2008

Journal of Translational Medicine 1/2008 Go to the issue

Research

Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors

Review

Pathways to ischemic neuronal cell death: are sex differences relevant?

Research

Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin

Editorial

Training the next generation of pluripotent stem cell researchers

Research

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

Research

Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits